London, United Kingdom, July 16, 2016 --(PR.com
)-- The industry established event “Orphan Drugs & Rare Diseases” returns to London on the 19th and 20th October 2016 for its 5th annual show. Robert Karl, Partner at RBV Capital, joins the list of expert speakers.
In the run up to the event, SMi spoke to Mr Karl about industry developments and his upcoming presentation which explores the key factors for building mutually beneficial and successful partnerships with venture capitals within the orphan drugs industry.
When asked about how he sees the future of the orphan drugs industry shaping up, Robert said, “The ‘orphan route’ to market has been a good way for start-ups (and big pharma companies) to gain faster and cost efficient access to the market and only then widening the nosology applications; it is even more incremental due to the regulatory, generic and payer’s pressure. The increasing pressure from payers for value differentiation and incremental benefit is one of the key drivers for future growth segments being potentially in the generic space when it comes to first line treatments and prevention whereas innovation seems to target more and more specialty pharmaceuticals. The orphan drug segment will remain a very attractive future segment for companies but also investors.”
The full interview is available to read in the event Download Centre at http://www.orphandrugs-event.com/prcom.
Robert worked in in global pharmaceutical companies for the last 22 years including Schering Plough, MSD and Mallinckrodt prior to joining RBV Capital as a partner. RBV is a life sciences venture capital fund that invests into innovative biomedical projects composed of early to market stage products.
Robert joins an expert speaker line-up which includes elite international speakers from Abeona, Action Duchenne, Alexion, BioMarin, Chiesi, Findacure, NICE, MHRA, and many more.
For further details, including registration details, visit the event website at http://www.orphandrugs-event.com/prcom.
Orphan Drugs & Rare Diseases 2016 is proudly sponsored by INC research. For details on tailored sponsorship and branding packages, contact Alia Malick on firstname.lastname@example.org.
For media enquiries, contact Honey de Gracia on email@example.com. For delegate enquiries contact Matthew Apps on firstname.lastname@example.org.
5th Orphan Drugs & Rare Diseases
19-20 October 2016
Holiday Inn Kensington Forum, London UK
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk